CA3157861A1 - Pharmaceutical formulations comprising niclosamide compound - Google Patents
Pharmaceutical formulations comprising niclosamide compoundInfo
- Publication number
- CA3157861A1 CA3157861A1 CA3157861A CA3157861A CA3157861A1 CA 3157861 A1 CA3157861 A1 CA 3157861A1 CA 3157861 A CA3157861 A CA 3157861A CA 3157861 A CA3157861 A CA 3157861A CA 3157861 A1 CA3157861 A1 CA 3157861A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- particle size
- size distribution
- niclosamide
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923290P | 2019-10-18 | 2019-10-18 | |
| US62/923,290 | 2019-10-18 | ||
| PCT/US2020/056027 WO2021076922A1 (en) | 2019-10-18 | 2020-10-16 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3157861A1 true CA3157861A1 (en) | 2021-04-22 |
Family
ID=75492817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3157861A Pending CA3157861A1 (en) | 2019-10-18 | 2020-10-16 | Pharmaceutical formulations comprising niclosamide compound |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210114973A1 (https=) |
| EP (1) | EP4045480A4 (https=) |
| JP (1) | JP2022553934A (https=) |
| KR (1) | KR20240039083A (https=) |
| CN (1) | CN117597327A (https=) |
| AR (1) | AR122323A1 (https=) |
| CA (1) | CA3157861A1 (https=) |
| TW (1) | TW202128610A (https=) |
| WO (1) | WO2021076922A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338783B1 (en) | 2014-09-12 | 2024-01-24 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| PE20181295A1 (es) | 2015-09-01 | 2018-08-07 | First Wave Bio Inc | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| WO2021174024A1 (en) * | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| GB202301306D0 (en) * | 2023-01-30 | 2023-03-15 | Ucl Business Ltd | Treatment of granulomatous disease |
| CN117357523A (zh) * | 2023-10-25 | 2024-01-09 | 澳门大学 | 利拉萘酯在制备预防和治疗肺纤维化药物中的用途 |
| CN117466786A (zh) * | 2023-12-25 | 2024-01-30 | 湖南一格制药有限公司 | 盐酸戊乙奎醚杂质及其制备方法 |
| WO2025207484A1 (en) * | 2024-03-25 | 2025-10-02 | Merveille.Ai | Use of aprepitant and cyclic dipeptide for weight control |
| CN118649135B (zh) * | 2024-07-18 | 2024-12-10 | 广东药科大学 | 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法 |
| CN119525016B (zh) * | 2024-12-24 | 2026-04-07 | 中国矿业大学 | 一种组合捕收剂及其在钾长石反浮选脱硅中的应用 |
| CN119431243B (zh) * | 2025-01-09 | 2025-06-10 | 万邦德制药集团有限公司 | 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用 |
| CN119841970B (zh) * | 2025-01-23 | 2026-02-27 | 集美大学 | 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用 |
| CN121406752A (zh) * | 2025-12-26 | 2026-01-27 | 圣湘生物科技股份有限公司 | 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2557615C2 (de) * | 1975-12-20 | 1985-08-14 | Bayer Ag, 5090 Leverkusen | Neue Niclosamid-Suspensionsformulierungen |
| NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
| AU2003249244A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| CN1546919A (zh) * | 2003-07-13 | 2004-11-17 | 叶声羽 | 桑拿浴房 |
| CN1626506A (zh) * | 2004-08-10 | 2005-06-15 | 李志良 | 高纯度、高收率氯硝柳胺的制备 |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| CN103751854B (zh) * | 2014-01-20 | 2015-08-26 | 瞿介明 | 抗菌医用导管 |
| PE20181295A1 (es) * | 2015-09-01 | 2018-08-07 | First Wave Bio Inc | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala |
| EP3168211A1 (en) * | 2015-11-10 | 2017-05-17 | Westfälische Wilhelms-Universität Münster | Pharmaceutical co-crystals of niclosamide |
-
2020
- 2020-04-07 US US16/842,695 patent/US20210114973A1/en not_active Abandoned
- 2020-10-16 KR KR1020227016634A patent/KR20240039083A/ko not_active Ceased
- 2020-10-16 TW TW109136022A patent/TW202128610A/zh unknown
- 2020-10-16 JP JP2022522825A patent/JP2022553934A/ja active Pending
- 2020-10-16 EP EP20877454.7A patent/EP4045480A4/en not_active Withdrawn
- 2020-10-16 CA CA3157861A patent/CA3157861A1/en active Pending
- 2020-10-16 CN CN202080088987.0A patent/CN117597327A/zh active Pending
- 2020-10-16 WO PCT/US2020/056027 patent/WO2021076922A1/en not_active Ceased
- 2020-10-19 AR ARP200102884A patent/AR122323A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW202128610A (zh) | 2021-08-01 |
| AR122323A1 (es) | 2022-08-31 |
| WO2021076922A1 (en) | 2021-04-22 |
| CN117597327A (zh) | 2024-02-23 |
| EP4045480A4 (en) | 2023-11-22 |
| EP4045480A1 (en) | 2022-08-24 |
| KR20240039083A (ko) | 2024-03-26 |
| US20210114973A1 (en) | 2021-04-22 |
| JP2022553934A (ja) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11793777B2 (en) | Methods and compositions for treating conditions associated with an abnormal inflammatory response | |
| US11564896B2 (en) | Methods of treatment | |
| CA3157861A1 (en) | Pharmaceutical formulations comprising niclosamide compound | |
| US7927613B2 (en) | Pharmaceutical co-crystal compositions | |
| WO2021188564A1 (en) | Methods of treating covid-19 with a niclosamide compound | |
| US20230102999A1 (en) | Deuterated niclosamide | |
| WO2023118074A1 (en) | Compressible and free flowing co-processed mesoporous silica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220412 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241004 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250825 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251128 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260416 |